Investigational drug · Phase 2
GTAEXS617
Also called: REC-617
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC).
Phase 2Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "GTAEXS617"
First trial start
2023
Jul 6, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GTAEXS617", any sponsor or status.
Conditions studied
As listed on its trial records.
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Pancreatic Adenocarcinoma
- Non-small Cell Lung Cancer (NSCLC)
- Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)
- Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma
- Triple Negative Breast Cancer (TNBC)
Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Pancreatic cancer · Head and neck cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "GTAEXS617" as an intervention, largest first.
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.Industry
NCT05985655 · 230 participants (planned) · Start Jul 6, 2023 · Primary completion Jan 2028
Drug: GTAEXS617; SoC · For: Head and Neck Squamous Cell Carcinoma (HNSCC); Pancreatic Adenocarcinoma; Non-small Cell Lung Cancer (NSCLC) and 3 more
Sites: Los Angeles, California; Grand Rapids, Michigan; New York, New York · 15 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Addressing Eroom's Law: The Shift Toward Clinically Driven Artificial Intelligence in Drug Discovery.
He JZ, Huo ZX, Wang CY, et al. · Curr Comput Aided Drug Des 2026
Also in development for Head and Neck Squamous Cell Carcinoma (HNSCC)
- INBRX-106OrdastobartPhase 31 trial
Inhibrx Biosciences, Inc · Head and Neck Squamous Cell Carcinoma (HNSCC), HPV Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC)
- AK129Phase 22 trials
Akeso · Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma
- AP203Phase 21 trial
AP Biosciences Inc. · Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC)
- FDC fianlimabPhase 21 trial
Regeneron · Head and Neck Squamous Cell Carcinoma (HNSCC)
- GEN1042Phase 21 trial
Genmab · Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
- MT-4561Phase 21 trial
Tanabe Pharma America, Inc. · Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.